Binds Virus Or Component Thereof Patents (Class 424/159.1)
  • Patent number: 10822398
    Abstract: Polyclonal antibodies specific for serogroup X of N. meningitidis and uses thereof in diagnosis. The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids without culture. The invention also concerns said polyclonal antibodies in different diagnostic tests and methods, in order to detect Nm X. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid, as well as a method for obtaining polyclonal antibodies useful for detecting NmX in biological fluids such as cerebrospinal fluid, serum and urine.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: November 3, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Muhamed-Kheir Taha, Alain Agnememel, Francois Traincard, Laurence Mulard
  • Patent number: 10799575
    Abstract: Described herein are flavivirus virus-like particles (VLPs) that display on their surfaces antigenic flavivirus proteins. Also described are methods of making and using these VLPs.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: October 13, 2020
    Assignee: TECHNOVAX, INC.
    Inventors: Jose M. Galarza, Helene Boigard, George Martin
  • Patent number: 10799454
    Abstract: An improved method for the manufacture of an oil-in water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) micro fluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration, of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: October 13, 2020
    Assignee: NOVARTIS AG
    Inventors: Gottfried Kraus, Robert Eskes
  • Patent number: 10786568
    Abstract: A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: September 29, 2020
    Assignees: The Trustees of the University of Pennsylvania, Janssen Biotech, Inc.
    Inventors: Maria P. Limberis, Anna P. Tretiakova, James M. Wilson, Michael Naso, Joost Kolkman, Robert Friesen, Qiang Wang
  • Patent number: 10738083
    Abstract: The present invention relates to novel peptidomimetic compounds that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses of phylogenetic group 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 11, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Maria Van Dongen, Christophe Francis Robert Nestor Buyck, Wim Bert Griet Schepens, Jaroslaw Juraszek, Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Boerries Brandenburg
  • Patent number: 10703802
    Abstract: The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 7, 2020
    Assignee: CELLTRION, INC.
    Inventors: Seung Suh Hong, Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Sung Hwan Kim, Eun Beom Lee, Jae Won Lee, So Jung Lee, Ji Young Shin, Myung Sam Cho
  • Patent number: 10653745
    Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: May 19, 2020
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventor: Benjamin S. Bleier
  • Patent number: 10551381
    Abstract: The present invention provides matched antibody pairs for the specific detection of one or more of the four dengue virus serotypes in a biological sample that may contain one or more of such dengue virus serotypes. Each matched antibody pair is capable of detecting not more than one serotype of dengue virus NS1 protein that may be present in the sample and will not cross react with other serotypes that may be present in the sample. Multiple matched pairs may be used to detect one or more dengue virus serotypes that may be present in a sample. Such matched pair antibodies, facilitate the development of confirmatory in vitro diagnostic tests such as sandwich immunoassays, that detect and distinguish the presence of one or more dengue virus serotypes in a biological sample, preferably a sample derived from human subject.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: February 4, 2020
    Assignees: Massachusetts Institute of Technology, The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Irene Bosch, Kimberly Hamad-Schifferli, Jose Gomez-Marquez, Helena de Puig, Lee Gehrke
  • Patent number: 10513553
    Abstract: This disclosure relates to peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 24, 2019
    Assignee: VISTERRA, INC.
    Inventors: Andrew M. Wollacott, Karthik Viswanathan, Jose Miguel Trevejo, Susan Sloan, Zachary Shriver, Maciej Boni
  • Patent number: 10487139
    Abstract: Disclosed are vaccine-derived neutralizing antibodies (NAbs) for CMV infections and small peptides which define precise recognition elements of the antigens by the NAbs. In certain embodiments, vaccine-derived NAbs may be produced by immunizing a subject with a gH/gL/UL128/UL130/UL131A pentameric glycoprotein complex (gH/gL-PC). In certain embodiments, vaccine-derived NAbs may have properties similar or identical to those of NAbs induced in a subject naturally infected with CMV. Native and non-native small peptides from UL128 and gH have been defined by mapping epitopes and deriving artificial sequences which are minimal recognition elements of vaccine-derived NAbs disclosed herein. These small peptides can be used to elicit vaccine-derived NAbs that prevent CMV entry into susceptible cell types and protect humans from infection and disease. Multivalent vaccines comprising these small peptides and/or epitopes are also disclosed.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: November 26, 2019
    Assignee: CITY OF HOPE
    Inventors: Don J. Diamond, Flavia Chiuppesi, Felix Wussow
  • Patent number: 10450368
    Abstract: The invention relates to the identification of monoclonal HIV-1 neutralizing antibodies, such as, but not limited to, antibodies that bind to the CD4 binding site (CD4bs) of HIV-1 gp120, their recombinant expression and purification and uses. In certain aspects, the invention provides a pharmaceutical composition comprising anyone of the antibodies of the invention or fragments thereof or any combination thereof. In certain aspects the invention provides methods to treat or prevent HIV-1 infection in a subject comprising administering to the subject a pharmaceutical composition comprising any one of the inventive antibodies or fragments thereof.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: October 22, 2019
    Assignee: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Hua-Xin Liao, Mattia Bonsignori
  • Patent number: 10450367
    Abstract: The invention provides human antibodies against rabies and methods of using the same.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: October 22, 2019
    Assignee: University of Massachusetts
    Inventors: William D. Thomas, Jr., Yang Wang
  • Patent number: 10370435
    Abstract: Monomeric and multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains including HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 6, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Boerries Brandenburg, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
  • Patent number: 10323257
    Abstract: The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 18, 2019
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz, Aemro Kassa
  • Patent number: 10301359
    Abstract: The present invention provides, among other things, technologies and methodologies for detection, treatment, and/or prevention of influenza transmission and/or infection. The present invention also provides technologies for monitoring influenza variants for their potential to present a pandemic risk to humans.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: May 28, 2019
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Ram Sasisekharan, Kannan Tharakaraman, Rahul Raman
  • Patent number: 10300127
    Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods. This invention addresses the above-described un-met need by providing an immune complex (IC) or immune complexes (ICs), which take advantages of Type II Fc receptor (FcR) interactions and signaling to elicit broader and more potent protective immune responses. In one aspect, the invention provides an immune complex comprising an antigenic agent and an isolated protein. The protein comprises an IgG Fc region and is capable of binding to a Type II Fc receptor. Preferably, the protein is an antibody or an Fc region-containing fragment thereof.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: May 28, 2019
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
  • Patent number: 10287315
    Abstract: The present invention relates to a method for purifying an immunoglobulin, and more particularly, to a method for purifying an immunoglobulin, which comprises: dialyzing and concentrating an immunoglobulin-containing plasma protein fraction II paste; removing thrombotic substances from the dialyzed and concentrated fraction by a purification process using ceramic cation exchange resin; and performing elution while maintaining salt concentration at a constant level to maintain the polymer content of the immunoglobulin at a low level. When the immunoglobulin purification method according to the present invention is used, the efficiency with which impurities and thrombotic substances are removed can be increased and the polymer content of the immunoglobulin can be maintained, and thus a stable immunoglobulin with improved quality can be produced.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: May 14, 2019
    Assignee: GREEN CROSS HOLDINGS CORPORATION
    Inventors: Ki-Hwan Son, Yong Kang, Dong-Hwarn Park, Sung Min Choi, Kang Yun Seo, Ki-Yong Kim
  • Patent number: 10266810
    Abstract: Described is a reproducible, effective and scalable process for parvovirus production including characterization strategies, preferably production of H-1PV.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: April 23, 2019
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Barbara Leuchs, Mandy Roscher, Marcus Müller, Jean Rommelaere
  • Patent number: 10253100
    Abstract: The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug a
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: April 9, 2019
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Futa Mimoto, Taichi Kuramochi
  • Patent number: 9969794
    Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 15, 2018
    Assignee: VISTERRA, INC.
    Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
  • Patent number: 9902764
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: February 27, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Kannan Tharakaraman
  • Patent number: 9890206
    Abstract: An antibody, or a binding fragment of the antibody, against H1N1 virus, includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region contains complementarity determining regions (CDR) that have the amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7; and wherein the light chain variable region contains complementarity determining regions that have the amino acid sequences of SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. A method for treating or preventing H1N1 infection in a subject includes administering to the subject the antibody or the binding fragment of the antibody.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: February 13, 2018
    Assignee: Medigen Biotechnology Corporation
    Inventors: Young-Sun Lin, Kuei-Tai Lai, Huei-Luen Huang, Hsiang-Ting Hsu, Wan-Chen Chen, Ya-Lin Chen, Chia-Wen Wong
  • Patent number: 9879066
    Abstract: The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Ning Chai, Jacqueline McBride, Lee Swem
  • Patent number: 9750799
    Abstract: GB1 peptidic compounds that specifically bind to a hemagglutinin target protein, and libraries that include the same, as well as methods of making and using the same, are provided. Also provided are methods and compositions for making and using the compounds. Also provided are hemagglutinin mimics and fragments and methods of using the same, including methods of screening for GB1 peptidic compounds and methods of using conjugates the mimics as influenza A vaccines. Aspects of the invention include methods of screening libraries of L-peptidic compounds for specific binding to a D-peptidic hemagglutinin target protein. Once a L-peptidic compound has been identified that specifically binds to the D-peptidic hemagglutinin target protein, the D-enantiomer of the selected L-peptidic compound may be produced. In some embodiments, the D-enantiomer of the selected L-peptidic compound binds to, and in some instances, neutralizes influenza virus particles.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: September 5, 2017
    Assignees: Reflexion Pharmaceuticals, Inc., The Governing Council of the University of Toronto
    Inventors: Dana Ault-Riche, Maruti Uppalapati
  • Patent number: 9714283
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: July 25, 2017
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, Jerrold B. Grossman, James Mond, Dov A. Goldstein
  • Patent number: 9683030
    Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 20, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
  • Patent number: 9611317
    Abstract: Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: April 4, 2017
    Assignee: Crucell Holland B.V.
    Inventors: Mark Throsby, Robert H. E. Friesen, Theodorus H. J. Kwaks, Mandy A. C. Jongeneelen
  • Patent number: 9598482
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: March 21, 2017
    Assignee: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 9587011
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 7, 2017
    Assignee: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 9475861
    Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: October 25, 2016
    Assignee: Celltrion Inc.
    Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
  • Patent number: 9457073
    Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: October 4, 2016
    Assignee: University of Manitoba
    Inventors: Marjolein Kikkert, Brian Leonard Mark, Puck Bertyne van Kasteren, Terrence William James, Eric John Snijder
  • Patent number: 9365635
    Abstract: A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titer individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titer individuals; and (d) purifying and/or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titer of specific antibodies is at least 5 times higher than the average titer of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 14, 2016
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Israel Nur, Liliana Bar, Orgad Laub
  • Patent number: 9309291
    Abstract: GB1 peptidic compounds that specifically bind to a hemagglutinin target protein, and libraries that include the same, as well as methods of making and using the same, are provided. Also provided are methods and compositions for making and using the compounds. Also provided are hemagglutinin mimics and fragments and methods of using the same, including methods of screening for GB1 peptidic compounds and methods of using conjugates the mimics as influenza A vaccines. Aspects of the invention include methods of screening libraries of L-peptidic compounds for specific binding to a D-peptidic hemagglutinin target protein. Once a L-peptidic compound has been identified that specifically binds to the D-peptidic hemagglutinin target protein, the D-enantiomer of the selected L-peptidic compound may be produced. In some embodiments, the D-enantiomer of the selected L-peptidic compound binds to, and in some instances, neutralizes influenza virus particles.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 12, 2016
    Assignees: Reflexion Pharmaceuticals, Inc., The Governing Council of the University of Toronto
    Inventors: Dana Ault-Riche, Maruti Uppalapati
  • Patent number: 9241986
    Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA-binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: January 26, 2016
    Assignee: KJ BIOSCIENCES LLC
    Inventor: Yawei Ni
  • Patent number: 9200063
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: December 1, 2015
    Assignee: POMONA RICERCA S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 9193780
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 24, 2015
    Assignee: Ablynx N.V.
    Inventors: Anna Hultberg, Bram Maassen, Peter Vanlandschoot, Erik Depla, Catelijne Stortelers, Cornelis Theodorus Verrips, Steven Van Gucht, Jose Melero, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Robert Anthony Weiss, Nigel J. Temperton, Xavier Saelens, Bert Schepens, Alexander Szyroki, Michael Marie Harmsen
  • Patent number: 9156905
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: October 13, 2015
    Assignee: VIB vzw
    Inventors: Serge Muyldermans, Viet Khong Nguyen
  • Patent number: 9132185
    Abstract: The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse genetics system for PRRSV; infectious chimeric PRRSV viruses generated through DNA shuffling; modified live-attenuated virus vaccines (MLV) using DNA shuffled chimeric viruses; chimeric viral proteins produced through shuffled chimeric viruses; PRRSV antigens and subunit vaccines based on shuffled chimeric viral proteins; and method of producing broadly protective PRRSV vaccines using DNA shuffling techniques.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: September 15, 2015
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Yanyan Ni, Yaowei Huang, Xiang-Jin Meng
  • Patent number: 9107906
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 18, 2015
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman
  • Patent number: 9096658
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: August 4, 2015
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Patent number: 9051357
    Abstract: The present invention provides modified fibronectin type III (Fn3) molecules, and nucleic acid molecules encoding the modified Fn3 molecules. Also provided are methods of preparing these molecules, and kits to perform the methods.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: June 9, 2015
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 9023348
    Abstract: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: May 5, 2015
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Yoram Reiter, Cyril Cohen
  • Publication number: 20150118250
    Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein said at least two recombinant nucleotide sequences are inserted into distinct non-coding region of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, the region located between SORF3 and US2.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 30, 2015
    Inventors: Ayumi Fujisawa, Mayumi Kubomura, Sakiko Saeki, Shuji Saito
  • Patent number: 9017668
    Abstract: Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: April 28, 2015
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • Publication number: 20150104446
    Abstract: Provided herein are methods and compositions for determining the susceptibility of infants to severe respiratory syncytial virus (RSV) infections. Also provide are methods of treating said subjects prophylactically to reduce the incidence of such infections.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventors: Fernando P. POLACK, Steven R. KLEEBERGER
  • Publication number: 20150104466
    Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.
    Type: Application
    Filed: October 16, 2013
    Publication date: April 16, 2015
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Teresa Compton, Adam L. Feire
  • Patent number: 9005624
    Abstract: Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: April 14, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Alexander Berthold Hendrik Bakker, Willem Egbert Marissen, Robert Arjen Kramer, Cornelis Adriaan De Kruif
  • Patent number: 9005621
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: April 14, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • Patent number: 9005623
    Abstract: The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: April 14, 2015
    Assignee: Sanofi Pasteur, SA
    Inventors: Catherine Moste, Isabelle Legastelois, Michel Chevalier, Laurent Thion
  • Patent number: 8992929
    Abstract: The present invention relates to the murine monoclonal antibody 4C2 or to chimeric or humanized monoclonal antibodies specific to a major neutralizing epitope of influenza H5 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using such murine or chimeric or humanized monoclonal antibodies or fragments thereof.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: March 31, 2015
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Prabakaran Mookkan, Fang He, Hwei-Sing Jimmy Kwang